[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349900-105":59,"doc-detail-349900-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mapping-research-trends-in-esophageal-cancer-immunotherapy-a-decade-of-thematic-evolution-and-emerging-priorities","Mapping research trends in esophageal cancer immunotherapy - A decade of thematic evolution and emerging priorities","","Immunotherapy has become a pivotal therapy for cancers including esophageal cancer, yet major barriers remain in identifying predictive biomarkers, optimizing combination strategies, and handling immunotherapy-related adverse effects. This bibliometric study mapped immunotherapy-focused publications in esophageal cancer from January 1, 2015 to October 14, 2024 using Web of Science Core Collection data. Analyses of keyword co-occurrence and co-citation identified leading contributors, central themes, and influential works. A total of 545 publications were included, with growth accelerating from 2019 and peaking between 2021 and 2023. China led output, and research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Temporal evolution showed early focus on immune checkpoint targets and agents, followed by mechanistic work on microenvironment, resistance, and prognosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mapping-research-trends-in-esophageal-cancer-immunotherapy-a-decade-of-thematic-evolution-and-emerging-priorities/349900/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mapping-research-trends-in-esophageal-cancer-immunotherapy-a-decade-of-thematic-evolution-and-emerging-priorities/349900.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What time span and data source does the bibliometric study cover?","Question",{"text":112,"@type":113},"The analysis covers publications from January 1, 2015 to October 14, 2024, retrieved from the Web of Science Core Collection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many publications were included in the analysis, and when did output accelerate?",{"text":117,"@type":113},"A total of 545 publications were included. Publication volume increased sharply starting in 2019, peaking between 2021 and 2023.",{"name":119,"@type":110,"acceptedAnswer":120},"Which research themes and targets were identified as hotspots?",{"text":121,"@type":113},"Hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation, with a temporal shift from early checkpoint-agent studies to mechanistic investigations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349900,1790725987,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2635243 [https://doi.org/10.1080/21645515.2026.2635243](https://doi.org/10.1080/21645515.2026.2635243)  \nRESEARCH ARTICLE     \nMapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities  \nHuijun Jiaa*, Yifan Gongb*, Chengguang Zhaoc, Hongyu Weia, and Qiwei Zanga  \naCardiothoracic Department, Suqian First Hospital, Suqian, Jiangsu, China; bFaculty of Medicine and Health Science, University Malaysia Sabah, Kota Kinabalu, Malaysia; cDigestive Department, Suqian First Hospital, Suqian, Jiangsu, China  \nABSTRACT  \nImmunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/ PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.  \nARTICLE HISTORY  \nReceived 14 July 2025 Revised 5 February 2026 Accepted 18 February 2026  \nKEYWORDS  \nEsophageal cancer;  \nimmunotherapy;  \nbibliometric analysis; research hotspots  \nIntroduction  \nEsophageal cancer represents a highly aggressive malignancy and remains one of the leading causes of cancer-related mortality worldwide, with over 600,000 new cases and approximately 540,000 deaths reported annually. 1 The disease burden shows marked geographic disparity – Eastern Asia, particularly China, accounts for more than half ofglobal cases and deaths, while relatively lower incidence is observed in North America and Europe.2 The two main types are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) . ESCC predominates in East Asia and Africa and is associated with lifestyle choices, including smoking, alcohol consumption,3 frequent intake of hot beverages, and consumption of pickled foods.4 In contrast, EAC is more common in Western countries, associated with chronic gastroesophageal reflux disease, Barrett’s esophagus, and obesity.5 These associations have been consistently confirmed in recent large-scale epidemiological studies and contemporary reviews.6 These subtypes not only differ in epidemiologic distribution and etiologic factors but also in their genomic landscapes. ESCC is characterized by frequent alterations in TP53, SOX2 amplification, and NOTCH1 mutations, while EAC commonly exhibits mutations in TP53, ERBB2 (HER2), and KRAS.7 Despite advances in surgery,8 radiotherapy, and chemotherapy,9 these conventional treatments have limited effic","cbCair7mqQOF6l2F","https://ap.wps.com/l/cbCair7mqQOF6l2F","pdf",6499465,17,"English","# Abstract\n# Introduction\n## Esophageal cancer burden and subtypes\n## Immunotherapy background and PD-1/PD-L1 axis\n# Keyword and citation-based bibliometric mapping\n## Publication output over time\n## Key contributors and institutions\n## Thematic hotspots and temporal shifts","[{\"question\":\"What time span and data source does the bibliometric study cover?\",\"answer\":\"The analysis covers publications from January 1, 2015 to October 14, 2024, retrieved from the Web of Science Core Collection.\"},{\"question\":\"How many publications were included in the analysis, and when did output accelerate?\",\"answer\":\"A total of 545 publications were included. Publication volume increased sharply starting in 2019, peaking between 2021 and 2023.\"},{\"question\":\"Which research themes and targets were identified as hotspots?\",\"answer\":\"Hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation, with a temporal shift from early checkpoint-agent studies to mechanistic investigations.\"}]","Mapping research trends in esophageal cancer immunotherapy - A decade of thematic evolution and emerging priorities | PDF",1790086144,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbc223f289698720bd807764de2b01ff.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe3a1502644158d1315f99acd8a85ca3.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f047bccf6565a861906fad97aaf0580a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19f6ad0ad1ead936c3d2de0800a0c238.webp",980,1306]